Australian Clinical Labs (ASX:ACL) Growth Rank: 5 (As of Sep. 16, 2026) — Near Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:ACL Australian Clinical Labs Ltd ASX:ACL
73 GF Score
Price A$2.84
GF Value A$2.95
Valuation Fairly Valued
! 8 Warning Signs
View Full Analysis

What is Australian Clinical Labs Growth Rank?

Australian Clinical Labs ASX:ACL +0.71% 73 Growth Rank is 5 as of Sep. 16, 2026, which is at its 10-year median of 5.00. GuruFocus rates ASX:ACL with a GF Score™ of 73/100 and a GF Value™ of A$2.95 (Fairly Valued). The stock has 8 warning signs investors should review.

Australian Clinical Labs has the Growth Rank of 5.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Australian Clinical Labs Growth Rank Related Terms

ASX:ACL vs TMO, DHR, NTRA: Growth Rank Comparison

For the Diagnostics & Research subindustry, Australian Clinical Labs's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Australian Clinical Labs Growth Rank vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Australian Clinical Labs's Growth Rank distribution charts can be found below:

* The bar in red indicates where Australian Clinical Labs's Growth Rank falls into.


ASX:ACL
73GF Score
Australian Clinical Labs Ltd ASX:ACL
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Growth Rank →
What does a Growth Rank of 5 mean?
Australian Clinical Labs (ASX:ACL) has a Growth Rank of 5 as of Sep. 16, 2026. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Australian Clinical Labs and its competitors. This is near median its historical median of 5.00. Over the past decade, Australian Clinical Labs' Growth Rank has ranged from 5.00 to 5.00.
Is Australian Clinical Labs' Growth Rank too high?
Australian Clinical Labs' current Growth Rank of 5 is near median its 10-year median of 5.00. Over the past 10 years, this metric has ranged from a low of 5.00 to a high of 5.00. Overall, Australian Clinical Labs has a GF Score™ of 73/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Australian Clinical Labs' Growth Rank compare to TMO and DHR?
Australian Clinical Labs' Growth Rank of 5 can be compared against companies in the Medical Diagnostics & Research industry. Historically, Australian Clinical Labs' own Growth Rank has ranged from 5.00 to 5.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Growth Rank for a Medical Diagnostics & Research company?
A good Growth Rank depends on the Medical Diagnostics & Research industry context. However, Growth Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Growth Rank mean?
A high Growth Rank can signal that a stock is expensive relative to its fundamentals. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Australian Clinical Labs and its competitors. Australian Clinical Labs's current Growth Rank is 5, which is near median its own 10-year median of 5.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Australian Clinical Labs stock overvalued right now?
Based on GuruFocus' analysis, Australian Clinical Labs (ASX:ACL) is currently considered Fairly Valued. The stock's GF Value™ is A$2.95, compared to a current price of A$2.84 — trading 3.7% below its estimated fair value. The current Growth Rank is 5, which is near median its 10-year median of 5.00. Australian Clinical Labs' overall GF Score™ is 73/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Growth Rank calculated?
Growth Rank is calculated from a company's financial statements. For Australian Clinical Labs (ASX:ACL), the current Growth Rank is 5 as of Sep. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Australian Clinical Labs (ASX:ACL) Overvalued in 2026?

Based on GuruFocus' analysis, Australian Clinical Labs stock appears to be undervalued. The current stock price of A$2.84 is trading 3.7% below its estimated GF Value™ of A$2.95. GuruFocus considers Australian Clinical Labs to be Fairly Valued.

Key valuation signals for ASX:ACL:

  • Growth Rank: 5 (near median its 10-year median of 5.00)
  • GF Value™: A$2.95 vs. price of A$2.84 (3.7% below fair value)
  • GF Score™: 73/100 with 8 warning signs

No single metric tells the full story. See the ASX:ACL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Australian Clinical Labs Business Description

Address 1868-1892 Dandenong Road, Clayton, VIC, AUS, 3168
Australian Clinical Labs is Australia's third-largest private pathology provider. ACL earns almost its entire group revenue from pathology services in Australia, which are mostly earned via the publicly funded health Medicare system. ACL is well established in the states of Western Australia, South Australia, Victoria, and the Northern Territory.
73GF Score

Get the complete analysis for ASX:ACL

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$2.84
Price
A$2.95
GF Value